Information letter to healthcare professionals regarding the medicinal product MAXICIN®, solution for infusion, 400 mg/250 ml. Fluoroquinolones for systemic and inhalation use – reminder of restrictions on use (risk of persistent severe adverse reactions)

27.05.2026 331 review

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу: МАКСІЦИН®, розчин для інфузій, 400мг/250 мл. Фторхінолони для системного та інгаляційного застосування – нагадування про обмеження застосування (ризик постійних тяжких побічних реакцій)PDF · 250 КБ

Завантажити

Information letter to healthcare professionals regarding the medicinal product MAXICIN®, solution for infusion, 400 mg/250 ml. Fluoroquinolones for systemic and inhalation use – reminder of restrictions on use (risk of persistent severe adverse reactions)

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product MAXICIN®, solution for infusion, 400 mg/250 ml. Fluoroquinolones for systemic and inhalation use – reminder of restrictions on use (risk of persistent severe adverse reactions)

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration